The Pharma Letter features a major milestone for Dewpoint Therapeutics – the nomination of our first development candidate, DPTX3186, as a […]

The Pharma Letter features a Dewpoint Therapeutics company profile, discussing our revolutionary condensate science with broad applicability across therapeutic areas, AI-powered […]

BOSTON, Massachusetts, June 25, 2024 – Just over a year after the start of its collaboration, Dewpoint Therapeutics and Novo Nordisk have […]

BOSTON, Massachusetts, June 24, 2024 – Dewpoint Therapeutics Inc., a biotechnology company that is translating the novel science of condensates into breakthrough […]

The Pharma Letter features an interview with our CEO Ameet Nathwani: “Dewpoint Therapeutics was founded on the ground-breaking realization that […]

Dewpoint congratulates our scientific founder, Tony Hyman, for his election to the German Academy of Sciences Leopoldina. This prestigious award […]

A Nature review of condensate focused start-ups has described Dewpoint as the “field’s frontrunner’. The article has profiled three condensate […]

The announcement of Dewpoint Therapeutics successful $77 million Series B raise has received significant attention in from both Industry and […]

Dewpoint congratulates its co-founder, Tony Hyman, who was this week elected to the National Academy of Sciences in honor of his […]

Dewpoint congratulates its co-founder Tony Hyman, for receiving the NOMIS Foundation’s Distinguished Scientist and Scholar Award.  The award recognises outstanding contributions […]